Transactions

QOL Medical recapitalized by an investor group led by Cooper Capital

Nov. 2010

Our Client: QOL is a rare disease pharmaceutical company that markets Sucraid for the treatment of Congenital Sucrase-Isomaltase Disorder (CSID)

Our Role: Edgemont Partners acted as exclusive financial advisor to QOL Medical in its recapitalization by Cooper Capital

Location: Vero Beach, FL

Sector: Pharmaceutical Services

View Press Release Connect with Lead Banker

QOL medical logo

recapitalized by an investor group led by

cooper capital logo
Get In Touch